Nontuberculous Mycobacterial Infection Market Analysis 2034 - Competitive Landscape, Clinical Trials, Market Share, Therapies, Prevalence, and Key Players by DelveInsight

In 2023, the Nontuberculous Mycobacterial (NTM) Infections Market in the United States was valued at around USD 360 million, and it is projected to grow throughout the 2024-2034 forecast period.

Nontuberculous Mycobacterial Market Overview
The NTM infections market is anticipated to expand consistently between 2024 and 2034, fueled by advancements in diagnostics, the introduction of novel therapies, and growing disease awareness. The aging population, which is more susceptible to NTM infections, continues to drive diagnosed case numbers upward.

Presently, treatment options rely mainly on repurposed or combination antibiotic regimens, as there are few new therapies available, leading to frequent relapses and treatment failures. ARIKAYCE remains the only FDA-approved treatment for refractory Mycobacterium avium complex (MAC) lung disease in adults. In 2023, the U.S. market stood at approximately USD 360 million, with ARIKAYCE contributing about USD 223 million.

Emerging drugs such as Epetraborole and MNKD-101 have the potential to reshape the treatment landscape, addressing current unmet needs and enhancing patient outcomes. Overall, continuous research and development and pipeline innovation are expected to accelerate market growth and improve the management of NTM infections.

DelveInsight's report, "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast - 2034," delivers an in-depth evaluation of NTM infections, highlighting historical trends, epidemiological projections, and market dynamics across the U.S., EU5 (Germany, Spain, Italy, France, and the UK), and Japan. The analysis covers current treatment practices, emerging therapeutic options, drug market shares, and forecasted market size (2020-2034) across the 7 major markets (7MM). Additionally, it explores treatment pathways, drivers, barriers, and unmet needs, pinpointing key opportunities and assessing market potential.

Explore the NTM Infections Market Landscape - uncover detailed epidemiological insights, growth forecasts, competitor analysis, and evolving treatment innovations @ Nontuberculous Mycobacterial Market Size - https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Nontuberculous Mycobacterial (NTM) Market Report
• The U.S. NTM infections market was valued at approximately USD 360 million in 2023 and is projected to witness steady growth through 2034.
• In July 2025, Insmed Incorporated announced results from ENCORE, a randomized, double-blind, placebo-controlled, multicenter Phase III study evaluating Amikacin Liposome Inhalation Suspension (ALIS) in adults with newly diagnosed Mycobacterium avium complex (MAC) lung infections.
• In December 2024, Shanghai MicuRx Pharmaceutical (688373.SH) reported that its anti-infective agent MRX-5 received FDA Orphan Drug Designation for NTM infections, marking a pivotal regulatory achievement.
• DelveInsight estimates approximately 108,000 diagnosed NTM cases in the U.S. in 2023, with numbers expected to rise due to aging populations, increasing chronic lung diseases (COPD, bronchiectasis), heightened awareness, and diagnostic advancements.
• Females represented roughly 68% of diagnosed cases in 2023, driven by biological, behavioral, and environmental factors.
• M. avium accounted for ~76,000 cases, followed by M. abscessus (~14,000) and other species (~18,000), largely due to environmental exposure.
• Pulmonary NTM infections (~86,000 cases) were significantly higher than extrapulmonary (~22,000 cases). Moderate cases (~58,000) were most common, followed by mild (~36,000) and severe (~13,000).
• Key players include AN2 Therapeutics, Mannkind, Spero Therapeutics, and Paratek Pharmaceuticals.
• Prominent drugs in development include SPR720, Molgramostim, Thiolanox, NUZYRA (omadacycline), CYT 107, and others.

Stay informed on the evolving Nontuberculous Mycobacterial Therapeutics Market with DelveInsight's Strategic Report @ Nontuberculous Mycobacterial Market Outlook - https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Nontuberculous Mycobacterial Epidemiology
DelveInsight's analysis indicates that around 108,000 individuals in the U.S. were diagnosed with NTM infections in 2023, with cases projected to rise from 2024 to 2034. This trend is driven by an aging demographic, increased chronic lung disease prevalence, and improved detection tools.
In 2023, females accounted for approximately 68% of diagnosed cases, compared to 32% in males, reflecting factors such as hormonal influences, immune responses, and higher chronic lung disease rates among women.
Nontuberculous Mycobacterial Epidemiology segmentation (7MM):
• Total prevalent and diagnosed NTM infection cases
• Gender-based and species-specific case distribution
• Type- and severity-specific segmentation

Explore detailed epidemiological insights across 7MM, including gender, species, and regional distributions @ Nontuberculous Mycobacterial Patient Pool - https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Nontuberculous Mycobacterial Infections Drug Uptake and Pipeline Overview
ARIKAYCE (Amikacin Liposome Inhalation Suspension) - Insmed
The first FDA-approved therapy for refractory MAC lung disease, ARIKAYCE utilizes Insmed's PULMOVANCE liposomal technology to deliver amikacin directly to the lungs, minimizing systemic toxicity. It is administered once daily via the Lamira Nebulizer System by PARI Pharma GmbH.

Epetraborole - AN2 Therapeutics
A novel, oral, once-daily therapy, Epetraborole (EBO) inhibits bacterial leucyl-tRNA synthetase (LeuRS), blocking protein synthesis in NTM pathogens.

MNKD-101 (Clofazimine Inhalation Suspension) - Mannkind Corporation
Designed to treat chronic and recurrent pulmonary infections, MNKD-101 is a nebulized form of clofazimine with FDA orphan drug, qualified infectious disease, and fast-track designations.

SPR720 (Fobrepodacin) - Spero Therapeutics
SPR720 is a broad-spectrum oral antibiotic targeting NTM pulmonary infections, including M. avium complex, M. kansasii, and M. abscessus, with a novel mechanism of action and no cross-resistance to existing antibiotics.

For a complete look at emerging trends and forecasts, explore DelveInsight's report @ Nontuberculous Mycobacterial Treatment Market - https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Nontuberculous Mycobacterial Market Outlook
The U.S. Nontuberculous Mycobacterial market, valued at about USD 360 million in 2023 (with ARIKAYCE contributing ~USD 223 million), is projected to maintain steady growth through 2034. Treatment requires long-term, multidrug regimens tailored to the species and infection site. Resistance and relapse remain significant challenges, making the development of targeted, effective therapies a key priority.

Nontuberculous Mycobacterial Market Drivers
• Increasing global prevalence of NTM infections
• Aging population and higher susceptibility
• Rising rates of COPD, bronchiectasis, and cystic fibrosis
• Advances in molecular and imaging diagnostics
• Expanding therapeutic pipeline (e.g., SPR720, Epetraborole, MNKD-101)
• Growing awareness among healthcare professionals and patients

Nontuberculous Mycobacterial Market Barriers
• Only one FDA-approved therapy (ARIKAYCE)
• High cost of treatment regimens
• Complex and prolonged therapy requirements
• Regulatory hurdles delaying approvals
• Frequent relapse and limited long-term efficacy

Discover how innovations, rising prevalence, and diagnostic progress are transforming the NTM market despite high costs and limited approvals @ Nontuberculous Mycobacterial Market Drivers and Barriers - https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Nontuberculous Mycobacterial Market Report Scope
• Coverage: 7MM (U.S., EU5, Japan)
• Study Period: 2020-2034
• Companies: AN2 Therapeutics, Mannkind, Spero Therapeutics, Paratek Pharmaceuticals, etc.
• Therapies: SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA, CYT 107, and more
• Analysis: Market dynamics, drivers, barriers, unmet needs, and expert insights

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.